9999999997-16-025738.txt : 20160913 9999999997-16-025738.hdr.sgml : 20160913 20160913142259 ACCESSION NUMBER: 9999999997-16-025738 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160913 DATE AS OF CHANGE: 20160913 20160913 20160913 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 161882645 BUSINESS ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 310 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 310 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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